Cargando…

Multiple sclerosis: early indicators of disease and assessing future risk

Detalles Bibliográficos
Autores principales:	Willis, M. D., Robertson, N. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Journal Club
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578118/ https://www.ncbi.nlm.nih.gov/pubmed/33030606 http://dx.doi.org/10.1007/s00415-020-10239-1

Ejemplares similares

Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2
por: Willis, M. D., et al.
Publicado: (2020)

Early MRI predictors of prognosis in multiple sclerosis
por: Davda, Nikunj, et al.
Publicado: (2019)

B cell treatments for multiple sclerosis
por: McLauchlan, D., et al.
Publicado: (2017)

Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
por: Allman, M., et al.
Publicado: (2022)

Continuous evolution of magnetic resonance imaging in multiple sclerosis
por: Tallantyre, E. C., et al.
Publicado: (2016)

Stem cell treatment for multiple sclerosis
por: Owen Pickrell, W., et al.
Publicado: (2016)

A role for the Epstein–Barr virus in multiple sclerosis aetiology?
por: Hrastelj, J., et al.
Publicado: (2022)

Advances in biomarker research in multiple sclerosis
por: Butterworth, Sara E., et al.
Publicado: (2016)

New rare genetic variants in multiple sclerosis
por: Harding, Katharine E., et al.
Publicado: (2018)

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies
por: Hrastelj, James, et al.
Publicado: (2017)

Advances in the use of stem cell transplants in the treatment of multiple sclerosis
por: Thomas, Rachel, et al.
Publicado: (2022)

Chronic traumatic encephalopathy: identifying those at risk and understanding pathogenesis
por: Willis, M. D., et al.
Publicado: (2017)

Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease
por: Willis, M. D., et al.
Publicado: (2018)

Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment
por: Kreft, Karim L., et al.
Publicado: (2022)

Physical activity as a risk factor for amyotrophic lateral sclerosis-findings from three large European cohorts
por: M, Hu, et al.
Publicado: (2020)

Neurotoxicity of novel cancer immunotherapies
por: Willis, M. D., et al.
Publicado: (2019)

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
por: McArthur, C., et al.
Publicado: (2023)

The exposome in respiratory diseases: multiple preventable risk factors from early life to adulthood
por: Savouré, Marine, et al.
Publicado: (2023)

Ice bucket challenge bears fruit for amyotrophic lateral sclerosis
por: Hrastelj, James, et al.
Publicado: (2016)

Amyotrophic lateral sclerosis: an update on treatments from clinical trials
por: Wynford-Thomas, Ray, et al.
Publicado: (2023)

Journal Club: Efficacy of Tocilizumab in Early Systemic Sclerosis–Related Interstitial Lung Disease
por: Tiwari, Vivekanand, et al.
Publicado: (2021)

Chronic traumatic encephalopathy: quantifying risk and clarifying pathogenesis
por: McLauchlan, D., et al.
Publicado: (2020)

Technology-assisted recovery of walking after spinal cord injury
por: MD, Willis, et al.
Publicado: (2019)

Socioeconomic status in neurological disorders: a modifiable risk factor?
por: Hrastelj, J., et al.
Publicado: (2022)

Treatments in Alzheimer’s disease
por: Malik, G. A., et al.
Publicado: (2017)

Repurposing drugs to treat neurological diseases
por: Massey, T. H., et al.
Publicado: (2018)

The role of TSPO PET in assessing neuroinflammation
por: Crawshaw, Ania A., et al.
Publicado: (2017)

The economic burden of chronic neurological disease
por: Wynford-Thomas, R., et al.
Publicado: (2017)

Preclinical retinal neurodegeneration in a model of multiple sclerosis: The Journal of Neuroscience 2012; 32(16):5585–5597
por: Mathur, Deepali, et al.
Publicado: (2012)

Creutzfeldt–Jacob disease: new directions in diagnosis and therapeutics
por: Al-Ansari, Aseel, et al.
Publicado: (2017)

Advances in the genetics of stroke risk and recovery
por: Majumder, Sabbiha Nadia, et al.
Publicado: (2022)

New treatments in Alzheimer’s disease
por: Pickrell, William O., et al.
Publicado: (2018)

Seizures in Alzheimer’s disease: is there more beneath the surface?
por: Edwards, Marc, et al.
Publicado: (2017)

New ways of looking at an old disease: the reimagination of epilepsy
por: Mitchell, Clinton J., et al.
Publicado: (2016)

Stem cells in the treatment of central nervous system disease
por: McLauchlan, Duncan, et al.
Publicado: (2018)

Reversing the trend: interventions to treat intracranial haemorrhage associated with anticoagulation
por: McLauchlan, D., et al.
Publicado: (2016)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Neurology and vaccinations: considerations in the context of COVID-19/SARS-COV-2
por: Cauchi, M., et al.
Publicado: (2021)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

Sleep disorders in Parkinson’s disease
por: Hawken, Jonathan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8gr8eqos5l6tqt1k29uhn0va24